News Sentiment

FBIO sentiment intelligence

Fortress Biotech Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 62 Constructive news tone 45 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.99 Week of 19 Jun 2026
Weighted tone 62/100

Constructive news tone

Market reaction News confirmed by price

Constructive news tone is being confirmed by positive weekly price action.

Primary event Market update

77/100 classification confidence.

Company focus 38

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

+7.9% over one week, +9.1% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Fortress Biotech Stock - Saturday deep dive on the business model

Market Reaction

News confirmed by price

71/100 confidence

Constructive news tone is being confirmed by positive weekly price action.

Primary event Market update 77/100 classification
One-week reaction 7.9% Price confirming higher
Trend fit Trend inactive 9.1% over four weeks
Fair value 11.3% Near fair-value range
Sentiment-trend disagreement

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 20
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 38
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 7
GlobeNewswire 4
AD HOC NEWS 3
TradingKey 3
MarketBeat 3
Stock Traders Daily 3
Seeking Alpha 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 20
Earnings 15
Regulatory and legal 6
Guidance 2
Deals and strategy 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 45
AD HOC NEWS Direct company coverage

Fortress Biotech Stock - Saturday deep dive on the business model

This article provides a deep dive into Fortress Biotech's business model, highlighting its "hub-and-spoke" structure through majority or minority-owned subsidiaries. The company acquires and develops biopharmaceutical product candidates in various therapeutic areas like oncology,

Tone
Positive 64/100
Event
Market update
Published
20 Jun 2026 18:43
Source
AD HOC NEWS
TradingKey Direct company coverage

Fortress Biotech Inc (FBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Fortress Biotech Inc (FBIO), highlighting its current price momentum score of 8.51 and its position between resistance and support levels. It details various technical indicators like MACD, RSI, and moving averages, offering buy/sell

Tone
Positive 65/100
Event
Market update
Published
18 Jun 2026 11:10
Source
TradingKey
TradingKey Direct company coverage

Fortress Biotech Inc (FBIO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Fortress Biotech Inc (FBIO) by TradingKey. It details the company's current valuation score of 9.14, ranking it 48th out of 157 in the Pharmaceuticals industry, and highlights its P/E ratio of 0.80. The article also notes that relevan

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 11:10
Source
TradingKey
GlobeNewswire Direct company coverage

Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Fortress Biotech (FBIO) reported strong first-quarter 2026 financial results, with consolidated net income attributable to common stockholders reaching $108.4 million or $3.44 per share (basic). Key drivers included the FDA approval of ZYCUBO® for Menkes disease and the subsequen

Tone
Positive 72/100
Event
Earnings
Published
13 May 2026 12:09
Source
GlobeNewswire
MSN Direct company coverage

Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher

Fortress Biotech (FBIO) has announced that Cyprium Therapeutics, a company in which Fortress owns a substantial equity stake, has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. This sale is expected to generate signifi

Tone
Positive 86/100
Event
Deals and strategy
Published
28 Apr 2026 23:39
Source
MSN
GlobeNewswire Direct company coverage

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech (Nasdaq: FBIO) announced its financial results for the full-year ended December 31, 2025, detailing significant corporate achievements including asset monetizations, regulatory approvals, and advancements in clinical programs. Key highlights include the FDA appro

Tone
Positive 71/100
Event
Earnings
Published
08 Apr 2026 12:39
Source
GlobeNewswire
Stock Titan Direct company coverage

Rare-disease voucher sale brings Fortress more than $100M

Fortress Biotech's subsidiary, Cyprium Therapeutics, has completed the sale of its Rare Pediatric Disease Priority Review Voucher for $205 million. Fortress Biotech anticipates receiving over $100 million from this transaction, which will enhance its financial flexibility for bus

Tone
Positive 90/100
Event
Market update
Published
30 Mar 2026 20:10
Source
Stock Titan
The Manila Times Direct company coverage

Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Fortress Biotech's subsidiary, Cyprium Therapeutics, has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. Fortress expects to receive over $100 million from the transaction, enhancing its financial flexibility. The PRV was issued fo

Tone
Positive 74/100
Event
Guidance
Published
30 Mar 2026 20:10
Source
The Manila Times
Stocktwits Direct company coverage

FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy

Fortress Biotech's shares rallied by 10% after its majority-owned unit, Cyprium Therapeutics, sold a Rare Pediatric Disease Priority Review Voucher for $205 million to Sentynl Therapeutics. The voucher was issued following the FDA approval of ZYCUBO for Menkes disease, and 20% of

Tone
Positive 74/100
Event
Regulatory and legal
Published
23 Feb 2026 17:08
Source
Stocktwits
Timothy Sykes Direct company coverage

Fortress Biotech Inc. Shares Soar After Promising New Developments

Fortress Biotech Inc. (FBIO) shares have risen by 9.97% due to positive market reactions to regulatory approvals, strategic partnerships, and strong revenue growth. The company reported $57.7M in revenue and an impressive 71.6% gross margin, with analysts remaining bullish on its

Tone
Positive 70/100
Event
Earnings
Published
23 Feb 2026 16:45
Source
Timothy Sykes
GlobeNewswire Direct company coverage

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Fortress Biotech's majority-owned subsidiary, Cyprium Therapeutics, has announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. This PRV was issued following the FDA approval of ZYCUBO for Menkes disease, with Sentynl Therapeutics

Tone
Positive 72/100
Event
Regulatory and legal
Published
23 Feb 2026 14:24
Source
GlobeNewswire
Quiver Quantitative Direct company coverage

Fortress Biotech, Inc. and Cyprium Therapeutics Enter Asset Purchase Agreement for $205 Million Rare Pediatric Disease Priority Review Voucher

Fortress Biotech, Inc. and its subsidiary Cyprium Therapeutics have agreed to sell a Rare Pediatric Disease Priority Review Voucher for $205 million. This voucher was obtained after the FDA approved ZYCUBO for Menkes disease, with Sentynl Therapeutics handling its commercializati

Tone
Positive 72/100
Event
Market update
Published
23 Feb 2026 14:08
Source
Quiver Quantitative
RTTNews Direct company coverage

Fortress Biotech's Cyprium To Sell $205 Million Priority Review Voucher; Shares Rise

Fortress Biotech's majority-owned subsidiary, Cyprium Therapeutics, has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. This follows the FDA approval of ZUCUBO for Menkes disease. Fortress Biotech (FBIO) shares rose 20% on the news, refle

Tone
Positive 74/100
Event
Regulatory and legal
Published
23 Feb 2026 10:12
Source
RTTNews
MarketBeat Direct company coverage

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - Here's What Happened

Fortress Biotech (NASDAQ:FBIO) shares have surpassed their 200-day moving average, trading as high as $3.54 and closing at $3.45 on Wednesday. The company holds a "Moderate Buy" consensus rating from analysts with a target price of $16.50. Wall Street Zen and Zacks recently upgra

Tone
Positive 66/100
Event
Analyst action
Published
19 Feb 2026 09:27
Source
MarketBeat
Stock Traders Daily Direct company coverage

Behavioral Patterns of FBIOP and Institutional Flows

This article analyzes Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents three AI-generated trading strategies—Position, Momentum Breakout

Tone
Neutral 50/100
Event
Guidance
Published
13 Feb 2026 14:28
Source
Stock Traders Daily
MarketBeat Direct company coverage

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - What's Next?

Fortress Biotech (NASDAQ:FBIO) shares have risen above their 200-day moving average, reaching $3.74 on high volume, which is considered a bullish technical signal. The company's fundamentals are mixed, with a market capitalization of $116 million and a negative P/E, but it recent

Tone
Positive 70/100
Event
Market update
Published
11 Feb 2026 07:58
Source
MarketBeat